Skip to main content
SpringerLink
Log in

Treatment of psoriasis

  • Chapter
  • First Online:
Handbook of Psoriasis and Psoriatic Arthritis

  • 1508 Accesses

Abstract

Treatment of psoriasis and psoriatic arthritis (PsA) can be challenging since a large variety of clinical conditions, different psoriasis types and patient factors need to be considered. Moreover, in the past decade, a large number of effective treatments have been developed and standards of management were consented.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate-to-severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1-10.

    Google Scholar 

  2. Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges. 2007;5:566-574.

    Google Scholar 

  3. Strober BE, Berger E, Cather J, et al. A series of critically challenging case scenarios in moderate- to-severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol. 2009;61:S1-S46.

    Google Scholar 

  4. Strober BE, Clay Cather J, Cohen D et al. A Delphi consensus approach to challenging case scenarios in moderate-to-severe psoriasis: part 1. Dermatol Ther (HeidelB). 2012;2:1.

    Google Scholar 

  5. Strober BE, Clay Cather J, Cohen D et al. A Delphi consensus approach to challenging case scenarios in moderate-to-severe psoriasis: part 2. Dermatol Ther (HeidelB). 2012;2:2.

    Google Scholar 

  6. Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28:438-453.

    Google Scholar 

  7. Augustin M, Holland B, Dartsch D, Langenbruch A, Radtke MA. Adherence in the treatment of psoriasis: a systematic review. Dermatology. 2011;222:363-374.

    Google Scholar 

  8. Neri L, Miracapillo A. Treatment adherence and real-life effectiveness of topical therapy in patients with mild or moderate psoriasis: uptake of scientific evidence in clinical practice and dermatologists’ preferences for alternative treatment options. G Ital Dermatol Venereol. 2015;150:19-26.

    Google Scholar 

  9. Blome C, Simianer S, Purwins S, et al. Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology. 2010;221:154-159.

    Google Scholar 

  10. Nast A, Boehncke WH, Mrowietz U, et al. S3 - Guidelines on the treatment of psoriasis vulgaris (English version). Update. Deutsche Dermatologische Gesellschaft (DDG); Berufsverband Deutscher Dermatologen (BVDD). J Dtsch Dermatol Ges. 2012;10 Suppl 2:S1-S95.

    Google Scholar 

  11. Augustin M, Mrowietz U, Bonnekoh B, et al. Topical long-term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges. 2014;12:667-682.

    Google Scholar 

  12. Singh S, Gopal J, Mishra RN, Pandey SS.Topical 0.05% betamethasone dipropionate: efficacy in psoriasis with once a day vs. twice a day application. Br J Dermatol. 1995;133:497-498.

    Google Scholar 

  13. English JS, Bunker CB, Ruthven K, Dowd PM, Greaves MW. A double-blind comparison of the efficacy of betamethasone dipropionate cream twice daily versus once daily in the treatment of steroid responsive dermatoses. Clin Exp Dermatol. 1989;14:32-34

    Google Scholar 

  14. Reich K, Zschocke I, Bachelez H, et al. Efficacy of a fixed combination of calcipotriol/ betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study. J Eur Acad Dermatol Venereol. 2015;29:1156-1163.

    Google Scholar 

  15. Augustin M, Mrowietz U, Bonnekoh B, et al. Topical long-term therapy of psoriasis with vitamin D3 analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. J Dtsch Dermatol Ges. 2014;12:667-682.

    Google Scholar 

  16. Ma L, Yang Q, Yang H, et al. Calcipotriol plus betamethasone dipropionate gel compared with calcipotriol scalp solution in the treatment of scalp psoriasis: a randomized, controlled trial investigating efficacy and safety in a Chinese population. Int J Dermatol. 2015 [Epub ahead of print]; doi:10.1111/ijd.12788.

    Google Scholar 

  17. Schröder JM, Kosfeld U, Christophers E. Multifunctional inhibition by anthralin in nonstimulated and chemotactic factor stimulated human neutrophils. J Invest Dermatol. 1985;85:30-34.

    Google Scholar 

  18. Weinstein GD, Koo JY, Krueger GG, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol. 2003;48:760-767.

    Google Scholar 

  19. Armstrong AW, Bagel J, Van Voorhees AS, Robertson AD, Yamauchi PS. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation. JAMA Dermatol. 2015;151:432-438.

    Google Scholar 

  20. Ramsay CA, Schwartz BE, Lowson D, Papp K, Bolduc A, Gilbert M. Calcipotriol cream combined with twice weekly broad-band UVB phototherapy: a safe, effective and UVB-sparing antipsoriatric combination treatment. The Canadian Calcipotriol and UVB Study Group. Dermatology. 2000; 200:17-24.

    Google Scholar 

  21. Brockow T, Schiener R, Franke A, Resch KL, Peter RU. A pragmatic randomized controlled trial on the effectiveness of highly concentrated saline spa water baths followed by UVB compared to UVB only in moderate to severe psoriasis. J Altern Complement Med. 2007;13: 725-732.

    Google Scholar 

  22. Brockow T, Schiener R, Franke A,Resch KL, Peter RU. A pragmatic randomized controlled trial on the effectiveness of low concentrated saline spa water baths followed by ultraviolet B (UVB) compared to UVB only in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2007;21:1027-1037.

    Google Scholar 

  23. De Leeuw J, Van Lingen RG, Both H, Tank B, Nijsten T, Martino Neumann HA. A comparative study on the efficacy of treatment with 585 nm pulsed dye laser and ultraviolet B-TL01 in plaque type psoriasis. Dermatol Surg. 2009;35:80-91.

    Google Scholar 

  24. Ring J, Kowalzick L, Christophers E, et al. Calcitriol 3 microg g-1 ointment in combination with ultraviolet B phototherapy for the treatment of plaque psoriasis: results of a comparative study. Br J Dermatol. 2001;144:495-499.

    Google Scholar 

  25. Youssef RM, Mahgoub D, Mashaly HM, El-Nabarawy E, Samir N, El-Mofty M. Different narrowband. UVB dosage regimens in dark skinned psoriatics: a preliminary study. Photodermatol Photoimmunol Photomed. 2008;24:256-259.

    Google Scholar 

  26. Petrozzi JW. Topical steroids and UV radiation in psoriasis. Arch Dermafo/.1983;119:207-210.

    Google Scholar 

  27. Serwin AB, Wasowicz W, Chodynicka B. Selenium supplementation, soluble tumor necrosis factor-alpha receptor type 1, and C-reactive protein during psoriasis therapy with narrowband ultraviolet B. Nutrition. 2006;22:860-864.

    Google Scholar 

  28. Coven TR, Burack LH, Gilleaudeau R, Keogh M, Ozawa M, Krueger JG. Narrowband UV-B produces superior clinical and histopathological resolution of moderate-to-severe psoriasis in patients compared with broadband UV-B. Arch Dermatol. 1997;133:1514-1522.

    Google Scholar 

  29. Snellman E, Klimenko T, Rantanen T. Randomized half-side comparison of narrowband UVB and trimethylpsoralen bath plus UVA treatments for psoriasis. Acta Derm Venereol. 2004;84:132-137.

    Google Scholar 

  30. Amornpinyokeit N, Asawanonda P. 8-Methoxypsoralen cream plus targeted narrowband ultraviolet B for psoriasis. Photodermatol Photoimmunol Photomed. 2006;22:285-289.

    Google Scholar 

  31. Gordon PM, Diffey BL, Mattews JNS, Farr PM. A randomised comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol. 1999;41:728-732.

    Google Scholar 

  32. Leenutaphong V, Nimkulrat P, Sudtim S. Comparison of phototherapy two times and four times a week with low doses of narrow-band ultraviolet B in Asian patients with psoriasis. Photodermatol Photoimmunol Photomed. 2000;16:202-206.

    Google Scholar 

  33. Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006;142:836-842.

    Google Scholar 

  34. Goldinger SM, Dummer R, Schmid P, Prinz Vavricka M, Burg G, Lauchli S. Excimer laser versus narrow-band UVB (311 nm) in the treatment of psoriasis vulgaris. Dermatology. 2006;213:134-139.

    Google Scholar 

  35. Kaur M, Oliver B, Hu J, Feldman SR. Nonlaser UVB-targeted phototherapy treatment of psoriasis. Cutis. 2006;78:200-203.

    Google Scholar 

  36. Grundmann-Kollmann M, Ludwig R, et al. Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. J Am Acad Dermatol. 2004;50:734-739.

    Google Scholar 

  37. Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med. 1974;291:1207-1211.

    Google Scholar 

  38. Gyulai R, Bagot M, Griffiths CE, et al. Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. J Eur Acad Dermatol Venereol. 2015;29:224-231.

    Google Scholar 

  39. Menting SP, Dekker PM, Limpens J, Hooft L, Spuls PI. Methotrexate dosing regimen for plaque- type psoriasis: a systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation. Acta Derm Venereol. 2015 [Epub ahead of print]; doi:10.2340/00015555-2081.

    Google Scholar 

  40. Shea B, Swinden MV, Tanjong Ghogomu E, et al. Folic acid or folinic acid for reducing side effects of methotrexate for people with rheumatoid arthritis. Cochrane Database Syst Rev. 2013;5:CD000951.

    Google Scholar 

  41. Paul C, Gallini A, Maza A, et al. Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol. 2011;25:2-11.

    Google Scholar 

  42. Thaci D, Brautigam M, Kaufmann R, Weidinger G, Paul C, Christophers E. Body-weight- independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. Dermatology. 2002;205:383-388.

    Google Scholar 

  43. Booij MT, Van De Kerkhof PC. Acitretin revisited in the era of biologics. J Dermatolog Treat. 2011;22:86-89.

    Google Scholar 

  44. Dogra S1, Yadav S. Acitretin in psoriasis: an evolving scenario. Int J Dermatol. 2014;53:525-538.

    Google Scholar 

  45. Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37-49.

    Google Scholar 

  46. Reich K, Burden AD, Eaton JN, Hawkins NS. Efficacy of biologics in the treatment of moderate to severe psoriasis: a network meta-analysis of randomized controlled trials. Br J Dermatol. 2012;166:179-188.

    Google Scholar 

  47. Mease PJ, Kivitz AJ, Burch FX, Siegel EL, Cohen SB, Ory P, Salonen D, Rubenstein J, Sharp JT, Tsuji W. Eta- nercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum. 2004;50:2264-2272

    Google Scholar 

  48. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130:478-486.

    Google Scholar 

  49. Tyring S, Gordon KB, Poulin Y, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719-726.

    Google Scholar 

  50. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304-1312.

    Google Scholar 

  51. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. New Engl J Med. 2003;349:2014-2022.

    Google Scholar 

  52. Zachariae C, Mork NJ, Reunala T, Lorentzen H, Falk E, Karvonen SL, Johannesson A, Clareus B, Skov L, Mork G, Walker S, Qvitzau S. The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. Acta Derm Venereol. 2008;88:495-501.

    Google Scholar 

  53. Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115.

    Google Scholar 

  54. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol. 2008;158:558-566.

    Google Scholar 

  55. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665-1674.

    Google Scholar 

  56. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675-1684.

    Google Scholar 

  57. Griffiths CE, Strober BE, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med. 2010;362:118-128.

    Google Scholar 

  58. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to- severe plaque psoriasis. J Am Acad Dermatol. 2007;56:e1-e15.

    Google Scholar 

  59. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate- to-severe psoriasis: a phase III, multicentre, doubleblind trial. Lancet. 2005;366:1367-1374.

    Google Scholar 

  60. Malakouti M, Brown GE, Wang E, Koo J, Levin EC. The role of IL-17 in psoriasis. J Dermatolog Treat. 2015;26:41-44.

    Google Scholar 

  61. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis-results of two phase 3 trials. N Engl J Med. 2014;371:326-338.

    Google Scholar 

  62. Driessen RJ, Bisschops LA, Adang EM, Evers AW, Van De Kerkhof PC, De Jong EM. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics. Br J Dermatol. 2010;162:1324-1329.

    Google Scholar 

  63. Schmitt JM, Ford DE. Work limitations and productivity loss are associated with health- related quality of life but not with clinical severity in patients with psoriasis. Dermatology. 2006;213:102-110.

    Google Scholar 

  64. Mrowietz U, de Jong EM, Kragballe K, et al. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2014;28:438-453.

    Google Scholar 

  65. Papp KA, Menter A, Strober B, et al. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2 b randomized placebo-controlled dose- ranging study. Br J Dermatol. 2012;167:668-677.

    Google Scholar 

  66. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181-1189.

    Google Scholar 

  67. Zhu B, Edson-Heredia E, Cameron GS, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to- severe plaque psoriasis. Br J Dermatol. 2013;169:1337-1341.

    Google Scholar 

  68. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190-1199.

    Google Scholar 

  69. Zhu B, Edson-Heredia E, Cameron GS, et al. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to- severe plaque psoriasis. Br J Dermatol. 2013;169:1337-1341.

    Google Scholar 

  70. Gordon KB, Leonardi CL, Lebwohl M, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71:1176-1182.

    Google Scholar 

  71. Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase II b randomized placebo-controlled trial. Br J Dermatol. 2015;173:930-939.

    Google Scholar 

  72. Tausend W, Downing C, Tyring S. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab. J Cutan Med Surg. 2014;18:156-169.

    Google Scholar 

  73. Coimbra S, Figueiredo A, Santos-Silva A. Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis. Core Evid. 2014;9:89-97.

    Google Scholar 

  74. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol. 2009;23:1-70. Erratum in: J Eur Acad Dermatol Venereol. 2010;24:117-118.

    Google Scholar 

  75. Gillard SE, Finlay AY. Current management of psoriasis in the United Kingdom: patterns of prescribing and resource use in primary care. Int J Clin Pract. 2005;59:1260-1267.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Manchester, Salford Royal Foundation Hospital, Manchester, UK

    Matthias Augustin & Marc Alexander Radtke

Authors
  1. Matthias Augustin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marc Alexander Radtke
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Manchester, United Kingdom

    Richard Warren

  2. Montreal, Québec, Canada

    Alan Menter

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Augustin, M., Radtke, M.A. (2016). Treatment of psoriasis. In: Warren, R., Menter, A. (eds) Handbook of Psoriasis and Psoriatic Arthritis. Adis, Cham. https://doi.org/10.1007/978-3-319-18227-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18227-8_5

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-18226-1

  • Online ISBN: 978-3-319-18227-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation